Key Highlights

  • Net product Revenue rose 12.3% to USD 268.9 million, slightly below the USD 272.1 million estimate.
  • Diluted EPS of USD 0.81 trailed the USD 1.09 estimate and the USD 0.87 earned a year earlier.
  • Royalties pushed cost of product sold to 30.0% of revenue, from 24.9% a year earlier.
  • Cash and investments totaled USD 1.05 billion against USD 150.0 million of Debt at quarter end.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) reported third quarter net product revenue of USD 268.9 million, up 12.3% from USD 239.5 million and just under the USD 272.1 million estimate. Diluted EPS of USD 0.81 fell short of the USD 1.09 estimate and below USD 0.87 a year earlier. Net Income was USD 48.2 million, compared with USD 50.9 million.

Revenue Drivers and Margin Pressure

The revenue increase reflected a 7.5% rise in units shipped and a 7% price increase taken in January 2026, partly offset by rebates that were higher by about 2.0%. For the first nine months, net product revenue grew 19.4% to USD 745.6 million, helped by a 14.9% rise in units.

Cost of product sold rose 35.3% to USD 80.7 million, or 30.0% of revenue versus 24.9% a year earlier. The company attributed the increase to higher royalties on net product revenue and new royalties tied to the Novitium license agreement. Gross Profit still rose to USD 188.2 million from USD 179.8 million.

Operating Spend, Earnings and Cash

Research and development expense rose to USD 71.7 million from USD 55.0 million, and sales and Marketing increased to USD 34.7 million from USD 29.5 million. General and administrative expense declined to USD 27.7 million from USD 29.8 million. Operating Income fell to USD 54.2 million from USD 65.5 million. Interest income rose to USD 8.4 million, and the tax charge dropped to USD 11.1 million from USD 16.6 million.

Nine month net income reached USD 156.1 million, up from USD 136.2 million, or USD 2.63 per diluted share versus USD 2.32. Operating Cash Flow over the period was USD 196.9 million, compared with USD 222.0 million, and included USD 57.0 million of acquired in-process Research and Development expense. At September 30, cash, cash equivalents and investments were USD 1.05 billion, against USD 150.0 million of debt. No shares were repurchased under the USD 200 million authorization during the quarter.

Pipeline Milestones on the Calendar

The company submitted a New Drug Application for Pitolisant GR, a gastro-resistant formulation, in June, and the FDA accepted it for full review with a target action date of April 1, 2027. Pitolisant HD is in two Phase 3 registrational trials, in narcolepsy and idiopathic hypersomnia, with topline data scheduled for 2027 and a target FDA date in 2028.

The TEMPO Phase 3 study of WAKIX in Prader-Willi Syndrome has topline data scheduled for mid-2027. Harmony also submitted an investigational new drug application for BP-205, an orexin-2 receptor agonist, in July.

Signposts for the Next Quarter

Third quarter EPS of USD 0.81 compares with USD 0.87 a year ago and the USD 1.09 estimate, while nine month EPS of USD 2.63 compares with USD 2.32. Net product revenue of USD 268.9 million compares with USD 745.6 million over nine months. Cash and investments of USD 1.05 billion sit against USD 150.0 million of debt, and quarterly research spending of USD 71.7 million compares with USD 55.0 million a year earlier.